Phase I/IIa clinical trial for Recessive Dystrophic Epidermolysis Bullosa using genetically corrected autologous keratinocytes

Z. Siprashvili\textsuperscript{1}, N.T Nguyen\textsuperscript{1}, E.S. Gorell\textsuperscript{1}, K. Loutit\textsuperscript{1}, Y. Dutt-Singkh\textsuperscript{1}, J. Nazaroff\textsuperscript{2}, P. Khuu\textsuperscript{1}, L. Furukawa\textsuperscript{1}, H.P. Lorenz\textsuperscript{1}, T.H. Leung\textsuperscript{2}, D.R. Keene\textsuperscript{3}, K.E. Rieger\textsuperscript{1}, P.A. Khavari\textsuperscript{1,4}, A.T. Lane\textsuperscript{1}, J.Y. Tang\textsuperscript{1}, M.P. Marinkovich\textsuperscript{1,4}, \textsuperscript{1}Stanford University, Stanford, CA, \textsuperscript{2}University of Pennsylvania, \textsuperscript{3}Shriners Hospital for Crippled Children, Portland, OR, \textsuperscript{4}VA Palo Alto, Stanford CA.

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is an inherited genetic skin disorder caused by mutations in the \textit{COL7A1} gene encoding type VII collagen (C7). Current therapy is limited to supportive palliation. We report the results of the ongoing Phase I/IIa clinical trial of ex vivo gene therapy for the treatment of severe RDEB. 6 adult RDEB subjects (mean age 26) enrolled in this trial carried various heterozygous \textit{COL7A1} mutations resulting in expression of only truncated C7 protein undetectable by C7 NC2 antibodies and displayed absent/sparse anchoring fibrils (AF) by EM. Autologous RDEB keratinocytes isolated from skin biopsies were transduced with GMP grade retrovirus carrying full-length \textit{COL7A1}. 6~35cm\textsuperscript{2} autologous epidermal sheets were grafted onto chronic wounds that were unhealed for a mean of 8.5 years. The primary endpoint of the Phase I/IIA trial is to evaluate wound healing compared to untreated baseline wound. Secondary endpoints included expression of full-length C7 and restoration of AF at 3 and 6 months. No serious adverse events were reported, and no replication competent virus has been detected for up to 3 years. At 3 months, 94\% (27/36 grafts), at 6 months, 67\% (16/24 grafts) and at 12 months 50\% (12/24 grafts) showed significant wound healing as defined as > 75\% healing compared with baseline. C7 expression and morphologically normal NC2 reactive AF were demonstrated at the basement membrane of graft biopsies for up to 2 years however expression gradually diminished over time. These data demonstrate that \textit{COL7A1} ex-vivo gene transfer has a favorable safety profile, as well as wound healing efficacy which correlates with molecular correction. Together these findings highlight the potential of cell based therapy in RDEB patients.